Team Hewins LLC Grows Stock Holdings in Grifols, S.A. (NASDAQ:GRFS)

Team Hewins LLC increased its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 11.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 40,818 shares of the biotechnology company’s stock after buying an additional 4,324 shares during the period. Team Hewins LLC’s holdings in Grifols were worth $273,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Sei Investments Co. lifted its holdings in shares of Grifols by 185.4% in the third quarter. Sei Investments Co. now owns 2,002,818 shares of the biotechnology company’s stock valued at $18,306,000 after purchasing an additional 1,300,978 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Grifols by 350.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,111 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 10,979 shares in the last quarter. International Assets Investment Management LLC acquired a new position in shares of Grifols in the fourth quarter valued at approximately $398,000. Cardinal Capital Management raised its position in shares of Grifols by 10.4% in the fourth quarter. Cardinal Capital Management now owns 93,616 shares of the biotechnology company’s stock valued at $1,082,000 after buying an additional 8,789 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Grifols by 38.5% in the fourth quarter. New York State Common Retirement Fund now owns 2,058,286 shares of the biotechnology company’s stock valued at $23,794,000 after buying an additional 572,439 shares during the last quarter.

Grifols Trading Down 0.7 %

Shares of NASDAQ:GRFS traded down $0.06 during trading on Thursday, reaching $8.85. The stock had a trading volume of 2,056,512 shares, compared to its average volume of 2,308,558. The business has a fifty day moving average price of $7.15 and a 200-day moving average price of $7.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.29 and a current ratio of 2.79. Grifols, S.A. has a fifty-two week low of $5.30 and a fifty-two week high of $12.15.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.